Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

The FDA’s move to lift the hold on Zentalis Pharmaceuticals’ sole clinical-stage drug may have been good news for the biotech ...

A judge has ruled against investor Alcon Research on the matter of blocking investee Aurion Biotech from debuting on the ...

Imperative Care has received a green light from the FDA for its large-bore catheter to help remove stroke-causing blood clots ...

Philips is parting ways with its worldwide emergency care business, including its catalog of automated external ...

Having shown last week that its opioid alternative can reduce post-surgery pain, Tris Pharma is back with another slice of ...

Demand slipped for several large contract research organizations last year, and a new report from William Blair analysts suggests these firms should brace for a similar R&D landscape in 2025.

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

Two months after launching Pep2Tango Therapeutics, VC firm Versant Ventures is unveiling another obesity-focused biotech in ...

Just days after President Trump imposed broad restrictions on communications, meetings, travel and public appearances at the ...

BioAge Labs has given up on its lead obesity candidate. Weeks after stopping a trial in response to phase 2 data, the biotech ...